Share on StockTwits

Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi sold 2,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $11.54, for a total transaction of $23,080.00. Following the completion of the transaction, the insider now directly owns 2,119,526 shares in the company, valued at approximately $24,459,330. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Eleven Biotherapeutics (NASDAQ:EBIO) traded up 2.21% during mid-day trading on Wednesday, hitting $11.11. 5,990 shares of the company’s stock traded hands. Eleven Biotherapeutics has a one year low of $9.502 and a one year high of $19.333. The stock’s 50-day moving average is $11.77 and its 200-day moving average is $12.95. The company’s market cap is $171.0 million.

Eleven Biotherapeutics (NASDAQ:EBIO) last released its earnings data on Wednesday, August 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.04. Analysts expect that Eleven Biotherapeutics will post $-1.84 EPS for the current fiscal year.

Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.

Receive News & Ratings for Eleven Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.